Lexaria Bioscience Corp.
LEXX
$0.62
$0.000.36%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.01% | -23.39% | -112.67% | -317.74% | -129.26% |
| Total Depreciation and Amortization | -39.50% | 15.32% | 74.31% | -59.11% | 0.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.10% | 270.17% | 22.44% | 2,019.23% | 13.20% |
| Change in Net Operating Assets | 376.69% | -286.04% | -550.98% | 260,300.00% | -23.48% |
| Cash from Operations | 63.90% | -39.69% | -183.07% | -141.75% | -130.68% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 61.36% | -493.61% | 11.82% | 51.05% | 67.00% |
| Cash from Investing | 86.51% | -126.87% | 11.82% | 51.05% | 5.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.05% | -- | -66.51% | -99.66% | 138.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20.05% | -- | -66.51% | -99.66% | 138.84% |
| Foreign Exchange rate Adjustments | -78.13% | 409.52% | 3,200.00% | -281.20% | -172.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.06% | -42.38% | -150.01% | -158.49% | 162.15% |